Runben Biotechnology Co Ltd Ordinary Shares - Class A

Runben Shares released its 2026 interim report on August 21, 2026. The company's total operating revenue was 1.054 billion yuan, net profit attributable to the parent company was 225 million yuan, and net cash inflow from operating activities was 189 million yuan. The company's latest asset-liability ratio was 8.20 percent, up 1.69 percentage points from the previous quarter and up 1.22 percentage points from the same period last year. The latest gross margin was 60.52 percent, the latest return on equity was 9.62 percent, and diluted earnings per share was 0.56 yuan. The company's latest total asset turnover was 0.43 times, and the latest inventory turnover was 2.95 times, down 0.05 times from the same period last year, a year-on-year decline of 1.51 percent. The company had 22,500 shareholders, and the top ten shareholders held 329 million shares, accounting for 81.33 percent of the total share capital.

Runben Shares released its 2026 interim report, with net profit attributable to the parent company of 225 million yuan, up 20.03% from the same period last year. Total operating revenue was 1.054 billion yuan, up 17.74% year-on-year, marking four consecutive years of growth. Net cash inflow from operating activities was 189 million yuan, up 41.38% year-on-year. The company's latest gross margin was 60.52%, up 1.42 percentage points from the previous quarter, achieving five consecutive quarters of increase. The latest return on equity was 9.62%, up 0.99 percentage points year-on-year. Diluted earnings per share were 0.56 yuan, up 21.74% year-on-year.